Poolbeg Pharma plc – Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel
Continued momentum in Poolbeg’s global intellectual property strategy
21 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Israeli Patent Office.
